Certara Divests Regulatory & Medical Writing Business for up to $135M to Sharpen Strategic Focus

summarizeSummary

Certara, Inc. is selling its Regulatory and Medical Writing business for up to $135 million, a strategic move to focus on its core Model-Informed Drug Development (MIDD) solutions.

check_boxKey Events

• Strategic Divestiture Agreement

  Certara entered a definitive agreement to sell its global medical writing and related regulatory services business to Veristat, LLC.

• Significant Cash Consideration

  The transaction includes $100 million in upfront cash, subject to adjustments, and up to $35 million in contingent earn-out payments, totaling up to $135 million.

• Focus on Core Business

  The divestiture is intended to sharpen Certara's strategic focus on its Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions.

• Material Business Segment Sold

  The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, representing a notable portion of the company's operations.

auto_awesomeAnalysis

Certara's agreement to sell its Regulatory and Medical Writing business for up to $135 million represents a significant strategic divestiture. This move aims to sharpen the company's focus on its core Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, aligning with its stated strategy to accelerate AI-integrated modeling and simulation. The transaction provides substantial capital that Certara intends to deploy for long-term value creation, and investors should monitor the updated 2026 guidance for the financial impact of this strategic shift.